Anika Therapeutics (ANIK) Scheduled to Post Earnings on Thursday

Anika Therapeutics (NASDAQ:ANIK) will be releasing its earnings data before the market opens on Thursday, October 31st. Analysts expect Anika Therapeutics to post earnings of $0.30 per share for the quarter. Anika Therapeutics has set its FY 2024 guidance at EPS.Parties that wish to listen to the company’s conference call can do so using this link.

Anika Therapeutics (NASDAQ:ANIK) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.24). Anika Therapeutics had a negative net margin of 44.45% and a positive return on equity of 0.94%. The company had revenue of $41.92 million during the quarter, compared to analyst estimates of $39.90 million. During the same period last year, the firm earned ($0.06) EPS. On average, analysts expect Anika Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Anika Therapeutics Price Performance

ANIK opened at $24.54 on Thursday. Anika Therapeutics has a 1 year low of $18.08 and a 1 year high of $29.11. The stock has a market cap of $357.96 million, a P/E ratio of -4.67 and a beta of 0.83. The firm has a fifty day moving average price of $25.09 and a 200 day moving average price of $25.79.

Analyst Ratings Changes

Separately, Barrington Research reaffirmed an “outperform” rating and set a $37.00 target price on shares of Anika Therapeutics in a research note on Tuesday.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.